Browse Studies — Arctuva

Phase 3

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prosta…

Oligometastatic Prostate Cancer (OMPC)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT05939414

Phase 1

Pilot Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and PD-1 Blockade, With Targeted Ablation of Resistant Lesions, in Patients With Non-Castrate Recurrent Oligometastatic Prostate Cancer

The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab …

Prostate Cancer PatientsNon-castrate Prostate CancerRecurrent Prostate Cancer+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of Wisconsin, MadisonNCT07090148

Phase 1

A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of JUR-003 in Adult Patients With Metastatic Prostate Cancer

JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-…

Metastatic Castration Resistant Prostate CancerOligometastatic Prostate Cancer (OMPC)Metastatic Hormone Sensitive Prostate Cancer

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Juri Biosciences, Inc.NCT07824349